Cytomegalovirus Immunoglobulin After Thoracic Transplantation: An Overview by Grossi, Paolo et al.
Supplement
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
84
09
3 
| 
do
wn
lo
ad
ed
: 
13
.3
.2
01
7Cytomegalovirus Immunoglobulin After Thoracic
Transplantation: An Overview
Paolo Grossi, MD, PhD,1 Paul Mohacsi, MD,2 Zoltán Szabolcs, MD, PhD,3 and Luciano Potena, MD, PhD4
Abstract:Cytomegalovirus (CMV) is a highly complex pathogen which, despite modern prophylactic regimens, continues to af-
fect a high proportion of thoracic organ transplant recipients. The symptomatic manifestations of CMV infection are compounded
by adverse indirect effects induced by the multiple immunomodulatory actions of CMV. These include a higher risk of acute rejec-
tion, cardiac allograft vasculopathy after heart transplantation, and potentially bronchiolitis obliterans syndrome in lung transplant
recipients, with a greater propensity for opportunistic secondary infections. Prophylaxis for CMVusing antiviral agents (typically oral
valganciclovir or intravenous ganciclovir) is now almost universal, at least in high-risk transplants (D+/R−). Even with extended pro-
phylactic regimens, however, challenges remain. The CMVevents can still occur despite antiviral prophylaxis, including late-onset
infection or recurrent disease, and patients with ganciclovir-resistant CMV infection or who are intolerant to antiviral therapy require
alternative strategies. The CMV immunoglobulin (CMVIG) and antiviral agents have complementary modes of action. High-titer
CMVIG preparations provide passive CMV-specific immunity but also exert complex immunomodulatory properties which aug-
ment the antiviral effect of antiviral agents and offer the potential to suppress the indirect effects of CMV infection. This supplement
discusses the available data concerning the immunological and clinical effects of CMVIG after heart or lung transplantation.
(Transplantation 2016;100: S1–S4)Cytomegalovirus (CMV) (Figure 1) is one of the mostcommon pathogens in humans, infecting more than
60% of the general population and as many as 100%within
some geographic areas. In the immunocompetent host, itReceived 5 July 2015. Revision requested 15 October 2015.
Accepted 12 November 2015.
1 Department of Infectious and Tropical Diseases, University of Insubria, University
Hopital Ospedale di Circolo-Fondazioni Macchi, Varese, Italy.
2 Department of Cardiology, Swiss Cardiovascular Center, University Hospital Bern,
Switzerland.
3 Semmelweis University Heart and Vascular Center, Budapest, Hungary.
4 Heart and Lung Transplant Program, Cardiovascular Department, Academic Hos-
pital Sant' Orsola Malpighi Bologna, Bologna, Italy.
All authors received an honorarium from Biotest AG to attend the meeting upon
which this publication is based. Paolo Grossi is a member of a speaker's bureau
and advisory board for Biotest AG. Paul Mohacsi and Zoltán Szabolcs have no
other conflicts of interest to declare.
This supplement was funded by Biotest AG, Dreieich, Germany.
All authors attended a meeting to discuss the content of this supplement and review
the available evidence, after which the article was developed by a freelance medical
writer. All authors undertook a detailed critique of draft texts and approved the final
article for submission.
Correspondence: Paolo Grossi MD, PhD, Department of Infectious and Tropical
Diseases, University of Insubria, University Hopital "Ospedale di Circolo-Fondazioni
Macchi" Viale Borri, 57, 21100 Varese, Italy (paolo.grossi@uninsubria.it).
Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. This is an open-
access article distributed under the terms of the Creative Commons Attribution-
Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible
to download and share the work provided it is properly cited. The work cannot be
changed in any way or used commercially.
ISSN: 0041-1337/16/10003-S1
DOI: 10.1097/TP.0000000000001094
Transplantation ■ March 2016 ■ Volume 100 ■ Number 3Susually has a benign, asymptomatic course, but in the immu-
nocompromised or immune-immature host—such as trans-
plant recipients or newborns—it may develop clinically
meaningful clinical syndromes. The biology of CMV lifecycle
is among the most complex of the known human viruses
thanks to its ability to interact with the immune system via sev-
eral strategies by which it modulates and escapes host immune
response.1 Indeed, fewer than 30% of CMV genes are re-
quired for virus replication and many of the others relate to
regulation of the host's cellular mechanisms.2,3 Despite inten-
sive efforts to reduce the toll of CMV infection after thoracic
transplantation, it remains the most clinically relevant infec-
tious agent in this setting, representing a major cause of
morbidity and, if untreated, mortality. The intense immuno-
suppression required after heart or lung transplantation
compared with other solid organ transplants places these re-
cipients at particularly high risk for CMV events, com-
pounded after lung transplantation by a high transfer of
latent CMV in grafts from seropositive donors.
Despite the long experience with CMV immunoglobulin
(CMVIG) in thoracic organ transplantation, there is still a
wide variability among centers regarding its use in the pro-
phylaxis and treatment of CMV infection or CMV disease
(Table 1). Randomized trials are rare in this setting4 such that
evidence-led decision-making, although desirable, is difficult.
Against this background, a meeting of heart and lung trans-
plant experts was convened in San Diego, CA, in April
2014. The purpose of the discussions was to review the
available data relating to CMVIG therapy in the setting
of thoracic organ transplantation and to consider the most
appropriate strategies for its deployment to help reduce the
impact of CMV infection on patient outcomes. The keywww.transplantjournal.com S1
FIGURE 1. The CMV virion.
TABLE 1.
Possible settings for CMVIG administration in thoracic organ
transplantation
Component of universal prophylaxis in D+/R− transplants, in combination with
antiviral therapy
Intolerance to antiviral therapy necessitating dose reductions or
withdrawal/interruption
Recurrent CMV disease, e.g., if unresponsive to antiviral therapy
Treatment of CMV disease in the presence of hypogammaglobulinemia
Treatment of ganciclovir-resistant CMV infection (clinically suspected or
laboratory confirmed) in addition to effective antiviral agents (cidovofir,
foscarnet, maribavir, or letermovir, according to the sensitivity of the
responsible strain)
Note that these are not evidence-based indications.
S2 Transplantation ■ March 2016 ■ Volume 100 ■ Number 3S www.transplantjournal.comfindings and conclusions of the expert panel are reported
in this supplement.
The Burden of CMV
Estimates of CMVinfection rates vary, partly due to differ-
ences in diagnostic criteria, but recent studies using modern
CMV prophylaxis regimens have reported incidences of
11% to 30% in heart transplant recipients5-8 and 20% to
40% in lung transplant recipients.9-11 Encouragingly, mark-
edly lower rates have been observed in patients treated with
a mammalian target of rapamycin inhibitor5,7,12,13 or given
extended antiviral prophylaxis.14
High-level CMV infection can manifest as the well-
characterized CMV syndrome typified by mononucleosis-like
fever. If the infection progresses to organ-invasive CMV dis-
ease, it most often affects the gastrointestinal system (colitis,
ulceration), the liver (hepatitis) and, particularly in lung trans-
plant recipients, the lungs (pneumonitis), with potentially life-
threatening consequences. In addition, however, persistent
low-level CMV infection can exert a number of damaging in-
direct effects.15 Notably, CMV infection seems to be associ-
ated with a significant increase in the risk of acute rejection
after thoracic transplantation even in the era of valganciclovir
prophylaxis.9 The CMV infection upregulates major histo-
compatibility complex antigens in the graft, likely by stimu-
lating interferon-γ production by activated CD4+ cells, thus
increasing graft immunogenicity16 and prompting rejection.
The CMV infection also promotes the development of cardiac
allograft vasculopathy after heart transplantation16-20 by trig-
gering an early inflammatory response in the graft vasculature,
ultimately leading to enhanced intimal thickness and a reduced
lumen.16 Similarly, there is evidence that CMV infection or
CMV pneumonitis increases the risk of bronchiolitis obliterans
syndrome (BOS) in lung transplant recipients,21-25 again by
provoking interferon-γ release by CD4+ cells26 and other im-
munomodulatory effects,27 although conflicting results have
been reported.28-30 The CMV infection is also associated with
an increased risk of opportunistic secondary infections, such
as invasive fungal disease, again due to CMV-induced modu-
lation of the host immune system.31
Issues in the Management of CMV
Host defences are severely curtailed in solid organ trans-
plant patients receiving chronic immunosuppression, partic-
ularly in the first weeks posttransplant when the high risk
of rejection necessitates potent regimens. Since the 1990s,
antiviral prophylaxis for CMV using antiviral agents hasbecome more widely used after heart32-34 or lung35,36 trans-
plantation, particularly in high-risk D+/R− transplants.35 Ev-
idence from kidney transplantation that extending antiviral
prophylaxis to a minimum of 6 months reduces the risk of
CMV disease37 has been mirrored in heart8,38 and lung39-41
transplantation. Prophylactic treatment for CMV after lung
transplantation is almost entirely based on oral valganciclovir,
preceded by intravenous ganciclovir at approximately half of
specialist centers.35 If, alternatively, a preemptive strategy is
followed, prevention of primary CMV infection or viral reac-
tivation from latency sites requires constant immune surveil-
lance. Preemptive therapy, although effective,42,43 seems to
be less frequently used than prophylaxis; 1 international sur-
vey reported its use in only 14% of lung transplant centers.36
Despite the improvements in CMV infection rates after
adoption of modern antiviral protocols, considerable chal-
lenges remain. Even using extended valganciclovir regimens
within the controlled environment of a clinical trial, CMV
infection occurs in at least 10% of heart6 and lung14,41 trans-
plant patients. Furthermore, late-onset primary CMV infec-
tion after withdrawal of antiviral agents routinely occurs in
a proportion of patients receiving universal prophylaxis,44,45
whereas cases of recurrent CMV disease and, in particular,
CMV strains resistant to ganciclovir or valganciclovir require
alternative treatment approaches, such as foscarnet.46 Patients
with severe hypogammaglobulinemia, for example, induced
by immunosuppressive therapies, such as mycophenolic acid,
are another instance in which conventional antiviral therapy
alone may not be adequate. Additionally, the dose-limiting
hematological side effects of ganciclovir47 can necessitate a
switch of strategy.
CMV Immunoglobulin Therapy
The highly sophisticated mechanisms by which CMV
modulates cell signalling pathways to adapt the host immune
system1 may support a rationale for a combination approach
to prevention and treatment of CMV infection. The CMVIG
and antiviral agents have complementary modes of action:
CMVIG eliminates virus particles before they reach the host
cell, whereas antiviral agents (ganciclovir, foscarnet and
cidofovir) target viral DNApolymerase to block viral replica-
tion within the cell. The importance of an effective immuno-
globulin G response to CMVinfection was highlighted by the
randomized VICTOR study, in which solid organ transplant
patients (predominantly kidney transplant recipients) with
negative CMV serostatus at the point when antiviral therapy
© 2016 Wolters Kluwer Grossi et al S3started were significantly more likely to develop recurrent
CMV disease than those who were positive for CMV
IgG.48 The high titers of CMVIG in commercial preparations
provide passive CMV-specific immunity in heavily immuno-
suppressed patients, neutralizing free viral particles by pro-
moting opsonization and phagocytosis, and stimulating
lysis by complement- and antibody-mediated responses. Af-
ter the initial viremic phase, CMVIG enhances the antibody-
dependent cellular cytotoxicity response to CMV infection
such that its effect peaks a fewweeks after first administration,
when cytokine-producingCD4+ cells are produced.As discussed
in the subsequent section “The immunology of posttransplant
CMVinfection: Potential effect of CMVimmunoglobulins on
distinct components of the immune response toCMV”CMVIG
has complex immunomodulatory properties. In addition to
augmenting the antiviral effect of antiviral agents, these may
potentially suppress the indirect effects of CMV infection,
such as allograft rejection, transplant vasculopathy, and BOS.
The CMVIG preparations are, essentially, concentrated
doses of endogenous immunoglobulins from healthy individ-
uals and as such, safety is not considered a major concern.
Adverse events are rare and where they occur are typically
mild injection site reactions. For example, in 1 series of 377
heart transplant recipients given CMVIG as sole prophylaxis,
all patients received the full dose without any overt side ef-
fects,49 confirmed in a smaller early series of 15 patients.50
Postmarketing surveillance for the Cytotect preparation
found only 4 events with a possible or certain relation to
CMVIG administration across a total of 13 716 applications
in 2286 patients during a 3-year period, comprising 1 case of
headache, 1 infusion-related reaction, and 2 cases of anti-
hepatitis B surface antibody positivity.51 Given this level of
safety, virtually all the studies described in this article do
not report safety endpoints, and little evidence of adverse
events associated with CMVIG is available in the literature.
CMV-specific hyperimmunoglobulin preparations have been
used to treat or prevent CMV infection after thoracic trans-
plantation formore than 30 years.52During that time, produc-
tion methods have evolved and now incorporate sophisticated
viral inactivation procedures which ensure high-quality and
safety profiles and generateCMV-specific immunoglobulin.53
Before effective antiviral agents became available, CMVIG
was used more widely than now to prevent CMV infection.
In the United States, data suggest that CMVIG is currently
given prophylactically in fewer than 10% of heart trans-
plant recipients overall,33,34 but with higher usage in D+/R−
patients (~40%).36 A recent international survey of lung
transplant centers also found that 30% to 40% use CMVIG
for prophylaxis in D+/R− transplants.35,36 Information
on the application of CMVIG therapy for the treatment
of established CMV infection or disease is more sparse,
but across all types of solid organ transplants, it has been
reported that approximately 10% of clinicians routinely
administer CMVIG as an adjunct to antiviral treatment,
mostly in D+/R− cases.36
Use of CMVIG in heart and lung transplant recipients has
increased in recent years, possibly in response to growing
problemswith CMVmanagement based on antiviral therapy
alone, notably the emergence of ganciclovir-resistant strains.
Current consensus recommendations, however, note that there
are only limited data to support prophylactic use of CMVIG
when appropriate antivirals are given.15,54 Guidelines fromthe Transplantation Society and the American Society of
Transplantation do not advise CMVIG prophylaxis after
kidney or liver transplantation, but include the option for
CMVIG as adjunctive therapy to antiviral prophylaxis
after heart or lung transplantation in high-risk D+/R− pa-
tients.15,54,55 Regarding use of CMVIG to treat CMV dis-
ease, the recommendations point out that the evidence is
unclear but suggest that it could be considered in severe
forms, such as pneumonitis.15,54,55
The relative scarcity of high-quality trials in this area pro-
hibits development of robust, evidence-based guidance. The
articles in this supplement discuss the available data concern-
ing the immunological and clinical effects of CMVIG as pro-
phylaxis or treatment for CMV infection after heart or lung
transplantation.REFERENCES
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